Program Description
LLS invites innovative and ambitious proposals that can lead to better treatments and cures for MCL. In particular, the goals of MCL2 are to better understand and develop therapeutic approaches for relapsed MCL. However, novel work focused on early disease intervention or improved risk stratification is of interest. LLS calls for the submission of creative proposals with the potential for high impact in MCL. Applications should address both transformative issues in MCL biology and promising new directions in MCL therapy.
Grant Funding Mechanisms
LLS is calling for inventive proposals that have the potential for high impact in the field of MCL. Research funding will provide support for two types of grants: Synergistic Team Award (STA) and Translational Grants (TRLs).
The Synergistic Team Award (STA) will support substantial, collaborative projects addressing a significant obstacle in understanding and treating MCL.
- Research program led by a single program director (PD)
- Research program must consist of 2-3 distinct but synergistic projects
- Two-three independent research groups (PI’s) working collaboratively; one of the PI’s may be the PD. PI’s may be at the same or different institutions
- Four years of funding
- Major Go/No Go decision after two years
- $3,000,000.00 total award; $750,000.00 per year
- Indirect costs capped at 10% of total award amount
- Annual site visit by LLS research staff
- Two grants are planned to be awarded
The Translational Grants (TRL) will fund new and innovative research that advances laboratory discoveries toward clinical application.
- Support for preclinical and/or biological research
- Project led by a single PI
- Three years of support
- Third year of funding dependent on progress assessment at end of year two
- $750,000.00 total award; $250,000.00 per year
- Indirect costs capped at 10% of total award amount
- Three grants are planned to be awarded